Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 1,290,000 shares, a drop of 20.4% from the August 15th total of 1,620,000 shares. Based on an average daily volume of 531,800 shares, the short-interest ratio is currently 2.4 days.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors own 14.33% of the company’s stock.
Brainstorm Cell Therapeutics Stock Performance
NASDAQ BCLI traded up $0.01 on Tuesday, hitting $0.27. 19,562 shares of the stock traded hands, compared to its average volume of 740,406. The business’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.42. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.08. The firm has a market capitalization of $19.19 million, a price-to-earnings ratio of -0.83 and a beta of 0.35.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on BCLI. StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics in a research report on Sunday. They issued a “hold” rating for the company. Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Thursday, July 11th.
Check Out Our Latest Report on Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- What Buybacks and Lower Rates Could Mean for Restaurant Brands
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.